Amneal Pharmaceuticals, Inc. Q2 FY2025 earnings call

• Specialty Segment: CREXONT for Parkinson's disease launch exceeded expectations, with U.S. market share ~2% and on track for >3% by year-end, targeting peak sales of $300M-$500M. Brekiya autoinjector for migraine approved, launching in October with peak sales potential of $50M-$100M. - GLP-1: Partnership with Metsera, building state-of-the-art manufacturing facilities for GLP-1 products. - Affordable Medicines: Launching 20-30 new products annually, with 15 launched in 2025, focusing on complex products like microspheres, liposomes, and 505(b)(2) injectables. - Operations: Global manufacturing infrastructure with investments in digitization/automation, and collaboration with ApiJect for U.S. injectable manufacturing. - Innovation: CREXONT Phase IV study on track, Brekiya autoinjector for migraine, Metsera collaboration on GLP-1, and a biosimilars in-licensing strategy with 3 commercialized and 5 in development.

Affordable Medicines: Revenue of $433 million, grew 1% on top of 14% growth in the prior year. Specialty: Revenue of $128 million, grew 23% year-over-year, with CREXONT contributing $11 million, RYTARY $9 million (up 19%), and UNITHROID $4 million (up 12%). AvKARE: Revenues of $163 million declined 4%, but gross margin increased by 540 basis points and operating income increased by 44%. Overall, Q2 revenues were $720 million, adjusted EBITDA was $184 million. For the first half, total company revenues grew 4%, adjusted EBITDA grew 12%, and adjusted EPS grew 50%.

• Raised 2025 revenue guidance to $3 billion to $3.1 billion. - Adjusted EBITDA guidance increased by about $15 million to $665 million to $685 million. - Adjusted EPS guidance increased by about $0.05 to $0.70 to $0.75. - Operating cash flow guidance increased by about $20 million to $300 million to $330 million.

• Tariffs: Uncertainty exists, but levers to mitigate, with no meaningful exposure to certain regions like Mexico, Canada, China, or Europe. - Generic Competition: Impact on RYTARY revenue due to potential generic launches. - Regulatory/Market Risks: For biosimilars and international launches, including uncertainties in regulatory approvals and market uptake in regions like India.

Q: On CREXONT and RYTARY, when will the Parkinson's franchise trough and return to growth?

A: Tasos said the trough is expected next year from a revenue perspective, but EBITDA drag this year will be offset by growth in other segments.

Q: Metsera collaboration profitability?

A: Chirag said margins are higher than generics due to upfront risk taken, with significant international opportunity in 20 markets including India.

Q: RYTARY generic launches, reimbursement, international regs?

A: Tasos on generics, Joe on reimbursement coverage above expectations, Chintu on international launches in Europe and India with timelines for late 2026/early 2027.

Q: Guidance, tariffs?

A: Tasos on stronger second half revenue due to new product launches and facility upgrades, Chirag on tariffs uncertainty but pharma exempted for now.

Q: Revenue guide, biosimilars vertical integration?

A: Tasos on AvKARE growth in second half, Chirag on biosimilars vertical integration as a race, disciplined and focused on growth while maintaining financial flexibility.